In contrast, we found that RAD21 mutations are associated with de novo AML, are rarely preceded by MDS or MDS/MPN, and are associated with de novo or pan AML molecular abnormalities, such as t(8;21), FLT3, and NPM1 mutations [24]. Here, FLT3 is linked to acute myeloid leukemia.